Overview of treatment and price of rubicatin for small cell lung cancer

Lubicatin, also known asLurbinectedin or Zepzelca, is a new type of small molecule cytotoxic drug designed specifically for adult patients with small cell lung cancer (SCLC). This drug was jointly developed by Jazz Pharmaceuticals and PharmaMar. Its mechanism of action is unique: it can tightly bind to guanine residues in the minor groove of DNA to form a special adduct, thereby changing the structure of DNA, further affecting the activity of DNA-binding proteins and DNA repair pathways, ultimately leading to tumor cell cycle disorder and cell death.

In June 2020, the U.S. Food and Drug Administration (FDA) officially approved the marketing of rubicatin, making it a new option for the treatment of adult patients with metastatic small cell lung cancer (SCLC) who have progressed after platinum-based chemotherapy. Its efficacy is very significant, especially in controlling disease progression and prolonging patient survival. According to clinical trial data, among patients treated with rubicatin, the overall effective rate was as high as 35.2%, the median duration of response reached 5.3 months, and the median progression-free survival was also extended to 3.9 months.

In addition to being approved in the United States, rubicartine has also been recognized in many countries and regions around the world and has been included in multiple authoritative cancer treatment guidelines. Although Rubicatin has not yet been officially launched in China, its excellent efficacy and safety have won widespread praise from the international medical community. For patients with small cell lung cancer, the emergence of rubicatin undoubtedly brings them new treatment hope and options.

For patients who are in urgent need of Rubicatin but it is not yet available in the country, they can consider purchasing it through foreign channels or seeking help from formal overseas medical consulting companies. The Rubicatin currently available on the market is the original version, produced by Spain's PharmanMar Biopharmaceutical Company and sold in Singapore and the United States. The drug has a specification of 4 mg. The market price in the United States is 91,000 yuan per box, while the price in Singapore is more affordable, only 34,000 yuan per box.